Click the Why column to see why an item matched the search.
| Match | Type | Why |
|---|
| Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis. | Academic Article |
Why?
|
| Preclinical efficacy of MEK inhibition in Nras-mutant AML. | Academic Article |
Why?
|
| Protein kinase Cd is a therapeutic target in malignant melanoma with NRAS mutation. | Academic Article |
Why?
|
| Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples. | Academic Article |
Why?
|